Involvement of PI3K/Akt pathway in prostate cancer. Potential strategies for developing targeted therapies;Implication de la voie PI3K/Akt dans le cancer de la prostate. Nouvelles stratégies pour concevoir des thérapies ciblées

Annales Pharmaceutiques Francaises

Volumn 63, Issue 1, 2005, Pages 69-75

  Pommery, N ^b   Henichart J P ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^b NONE

Author keywords

Farnesyltransferase; Kinases; PI3K Akt signalling; Prostate cancer

Indexed keywords

GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN KINASE B;

ARTICLE; CANCER GROWTH; CELL GROWTH; CELL MOTILITY; CELL SURVIVAL; ENZYME ACTIVITY; GENE; GENE MUTATION; PROSTATE CANCER; PTEN GENE;

EID: 14244255644     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4509(05)82253-9     Document Type: Article

References (38)

1. Canil CM, Tannock IF. Is there a role for chemotherapy in prostate cancer? Br J Cancer 2004; 1-7.
2. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Cristofano AD, Xiao A et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003; 1: 1-12.
3. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-21.
4. Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C et al. Pro-survival function of Akt/Protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J Biol Chem 2001; 276: 38361-9.
5. Gao N, Zhang Z, Jiang BH, Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003; 310: 1124-32.
6. Mitsiades CS, Mitsiades N, Koutsilieris M. The Akt pathway: Molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 2004; 4: 235-56.
7. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142: 4795-805.
8. Ghosh PM, Malik S, Bedolla R, Kreisberg JI. Akt in prostate cancer: possible role in androgen-independence. Curr Drug Metab 2003; 4: 487-96.
9. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62: 6141-5.
10. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004; 30: 1-17.
11. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol 1999; 3: 500-9.
12. Van der Poel HG. Smart drugs in prostate cancer. Eur Urol 2004; 45: 1-17.
13. Riesterer O, Tenzer A, Zingg D, Hofstetter B, Vuongt V, Pruschy M, Bodis S. Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy? Int J Radiat Oncol Biol Phys 2004; 58: 361-8.
14. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J et al. Protein kinases as targets for anti-cancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002; 93: 79-98.
15. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley PW et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001; 21: 499-512.
16. Bencteux E, Houssin R, Hénichart J-P. A short and unequivocal synthesis of 5-aminotetrazolo[1,5α]-quinazoline as a tricyclic analogue of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035). J Heterocyclic Chem 1997; 34: 1375-8.
17. Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 2004; 3: 299-307.
18. Bouey-Bencteux E, Loison C, Pommery N, Houssin R, Hénichart J-P. Synthesis and antiproliferative properties of 4-aminoquinazoline derivatives as inhibitors of EGF-receptor-associated tyrosine kinase activity. Anti-Cancer Drug Design 1998; 13: 893-922.
19. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide -dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002; 277: 27613-21.
20. Leng J, Han CA, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: Evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003; 38: 756-68.
21. Komander D, Kular GS, Schuttelkopf AW, Deak M, Prakash KR, Bain J et al. Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. Structure (Camb) 2004; 12: 215-26.
22. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide- dependent protein kinase-1 inhibitors. Cancer Res 2004; 64: 4309-18.
23. Lali FV, Hunt AE, Turner SJ, Foxwell BM. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 2000; 275: 7395-402.
24. Barbey S, Goossens L, Taverne T, Cornet J, Choesme V, Rouaud C et al. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg. Med Chem Lett 2002; 12: 779-82.
25. Pommery N, Taverne T, Telliez A, Goossens L, Charlier C, Pommery J et al. New COX-2/5-LOX inhibitors, apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. 2004, J Med Chem 2004; 47: 6-20.
26. Houssin R, Pommery J, Salaun M-C, Deweer S, Goossens J-F, Chavatte P, et al. Design, synthesis and pharmacological evaluation of new farnesyl protein transferase inhibitors. J Med Chem 2002; 45: 533-6.
27. Millet R, Domarkas J, Houssin R, Gilleron P, Goossens J-F, Chavatte P et al. Potent and selective farnesyltransferase inhibitors. J Med Chem, sous presse.
28. Prendergast GC, Davide JP, deSolms SJ, Giuliani E, Graham S, Gibbs JB et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 1994; 14: 4193-202.
29. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, et al. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302-9.
30. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272: 14459-64.
31. Lerner EA, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 1997; 15: 1283-8.
32. Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci 2001; 58: 1636-49.
33. Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000; 60: 1871-7.
34. Sebti SM, Der CJ. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 2003; 3: 945-51.
35. Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton A, Der CJ. The Ras-related protein Rheb is farnesylated and antagonizes ras signaling and transformation. J Biol Chem 1997; 272: 10608-15.
36. Aspuria PJ, Tamanoi F. The Rheb family of GTP-binding proteins. Cell Signal 2004; 16: 1105-12.
37. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation -dependent manner. J Biol Chem 2003; 278: 32493-6.
38. s6k pathway. J Biol Chem 1999; 274: 4743-8.